Names | |
---|---|
IUPAC name
(RS)-2-Bromo-N-carbamoyl-3-methylbutanamide[citation needed]
| |
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.007.115 |
EC Number |
|
KEGG | |
MeSH | Bromisovalum |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C6H11BrN2O2 | |
Molar mass | 223.070 g·mol−1 |
log P | 1.057 |
Acidity (pKa) | 10.536 |
Basicity (pKb) | 3.461 |
Pharmacology | |
N05CM03 (WHO) | |
Oral | |
Related compounds | |
Related ureas
|
Carbromal |
Related compounds
|
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Bromisoval (INN), commonly known as bromovalerylurea, is a hypnotic and sedative of the bromoureide group discovered by Knoll in 1907 and patented in 1909.[1] It is marketed over the counter in Asia under various trade names (such as Brovarin[2]), usually in combination with nonsteroidal anti-inflammatory drugs.
Chronic use of bromisoval has been associated with bromine poisoning.[3][4][5][6]
Bromisoval can be prepared by bromination of isovaleric acid by the Hell-Volhard-Zelinsky reaction followed by reaction with urea.